Alcobra Ltd (NASDAQ:ADHD)
Alcobra Ltd (NASDAQ:ADHD) shares hit a pre-market high of $1.45 on exceptionally heavy volumes. Currently, as of 9:42 AM EST, ADHD is trading at $1.26, near it pre-market low of $1.23. Share volume is heavy and if the pace continues throughout the trading day ADHD is set to trade at almost 60 times it 30-day, daily average volume. Trader chat rooms are abuzz with rumors about the company that StockNewsUnion.com cannot independently confirm.
In 2016, several companies issued ratings on Alcobra Ltd (NASDAQ:ADHD). Oppenheimer was the only firm to rank ADHD above a “Neutral” and gave the shares a rating of “Outperform”. In 2016, three other firms downgraded the shares to either “Hold” or “Sell”. One company, WBB Securities, upgraded ADHD from a “Sell” to a “Hold”. In 2017 the only firm to release a ratings update was Jeffries who downgraded ADHD shares from a “Buy” to a “Hold”. Analysts have a consensus target price on Alcobra Ltd (NASDAQ:ADHD) of $2.29.
Alcobra Ltd (NASDAQ:ADHD) has had a poor performance over nearly every metric. For the past month ADHD shares were down 6.61%, YTD the shares are down 46.19%, and for the year the shares are down almost 80%. ADHD has a 52-week low of $0.83 and a 52-week high of $5.59.
Alcobra Ltd (NASDAQ:ADHD) has never reported any sales so the fact that shareholders have experienced an EPS loss each year is no surprise. Unfortunately, the company continues to dilute ADHD shreholders. In 2012, 7.79 million shares were outstanding and that number has grown to 27.56 million for the end of 2016. Instritutions own 38.7% of the company but have been selling their shares over the last year.
Israeli-based Alcobra Ltd (NASDAQ:ADHD) is a pharmaceutical company focused on the development and commercialization of their proprietary drug, Metadoxine Extended Release (MDX), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS).
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. All information, or data, is provided with no guarantees of accuracy.
Don’t miss out! Stay informed on $ADHD and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.